Jupiter Life Line Hospitals Limited (JLHL.NS) Q3 FY2026 Earnings Call Transcript & Summary

Ladies and gentlemen, good day, and welcome to Jupiter Life Line Hospital Limited Q3 and 9M FY '26 Earnings Conference Call. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Dr. Ankit Thakker, Joint Managing Director and CEO. Thank you, and over to you, Mr. Thakker.

Good morning, everyone. Thank you for joining us on our earnings call to discuss the business and financial performance for Q3 and 9 months of FY '26. I hope you had an opportunity to review our results and investor presentation, which have been uploaded on the website and the stock exchanges. I'm joined today by Mr. Sivasis Sen, our CFO; Ms. Suma Upparatti, our Company Secretary and Compliance Officer; and our Investor Relations Advisors, SGA. I'm delighted to kick off this Monday morning call with a good news. Our hospital in Dombivli is ready to be launched. The 750,000-square-foot, 500-bed structure has been completed before time and on budget ahead of its planned launch in Q1 of FY '27. This was a phenomenal project execution effort wherein we were able to complete the entire construction for the 500 beds, fit-outs for over 300 beds and all biomedical equipment installation in just over 24 months and at a CapEx of roughly INR 425 crores. I want to take a moment here to thank all our partners in this project, beginning from the consultants, contractors, vendors, our own project team and also the regulatory authorities, all of whom went above and beyond to enable us to deliver this project. We also welcome all the doctors and the team members who have already come onboard to join us in our mission to deliver the kind of health care to the region around Dombivli that the community has come to expect from Jupiter over the last 2 decades. The hospital is slated to be inaugurated on February 15 and will commence full clinical operations thereafter. In the interest of operational efficiency, we will only begin operating 200 beds in Phase 1 and then ramp up capacity in a phased manner as the occupancy increases. A heads up for everyone on this call, though, that beginning next quarter, you will see a much higher depreciation load than you have seen so far and should also expect an EBITDA drag on the consolidated numbers for around the next 2 years before the new hospital can start contributing financially. The Pune South project construction has kicked off and is progressing well, and the Mira Road project is under regulatory approval process. Alongside this expansion, our existing hospitals continue to demonstrate steady operating momentum with no surprises or specific highlights to report other than the impact of the new labor code. Our PBT in this quarter is, therefore, impacted to the tune of INR 6.4 crores due to this exceptional onetime provision. I will give you the highlights of our consolidated financial performance now. The numbers for Q3 of this financial year. Total income stood at INR 365.3 crores in this quarter, an increase of 9.8% year-on-year. EBITDA stood at INR 83.4 crores, an increase of 9.2% year-on-year. The EBITDA margin is 22.8% in this quarter. The PAT stood at INR 42.5 crores, representing a decrease of 18.7% year-on-year and the margin for the quarter is 11.6%. The 9-month numbers. Total income is INR 1,111.9 crores, an increase of 15.1% year-on-year. The EBITDA is INR 254 crores, an increase of 15.2% year-on-year. The EBITDA margin is 22.8% for the 9-month period. The PAT is INR 143.9 crores for the 9-month period, a decrease of 3.1% year-on-year. As highlighted earlier, the PAT is impacted due to the new labor code changes and the margin is 12.9%. The ARPOB for the 9-month period is 66,800. The ALOS is 3.85 days and the average occupancy for 9 months is 61.9%. The payer mix, insurance represents 55.7%, self-payers 43.2% and government schemes at just around 1.1%. With this, I conclude my opening remarks and open the floor for questions and answers. Thank you.

[Operator Instructions] The first question comes from the line of [Manav Jain] from [Jain Investments].

Congratulations on the opening of the new hospital. My question is regarding the Pune Bibwewadi project. Could you please share an update on the current stage of the construction and the total CapEx incurred date for the hospital?

Thank you. So the Bibwewadi project is, as I said, construction has begun. We have just started the basement work. So it is in early stages of construction. The excavation is now over. As we have said that we are slated to begin sometime in calendar year '28. And we are reasonably sure to achieve that target. CapEx so far, as you can imagine, because it's only excavation and a little bit of basement is not very high but maybe less than INR 50 crores so far.

Okay, sir. And could you please share the total CapEx incurred during 9 months FY '26 and also provide hospital-wise CapEx for Dombivli and Pune facilities?

So Dombivli, as I said, INR 425 crores is the total that we have spent for the project. Pune, I can see a number of around INR 45 crores so far. Mira Road, we have not started.

Next question comes from the line of Ashutosh [Nemani] with JM Financial Family Office.

Am I audible?

Yes, Ashutosh, you are.

So my first question is regarding the ramp-up plan of Dombivli Hospital. So how do you anticipate occupancy ramp-up, if you can guide, let's say, for the next 3 to 4 quarters? And how would be the specialty mix? And what is the expected ARPOB of the hospitals?

So as I've said, you have to look at it in a longer term. The first 3-year period, we consider as a stabilization, foundational or maturity kind of period. And the next 3-year period, we consider as a rapid growth period. So these are long-term infrastructure kind of community assets, and we don't really look at it quarter-to-quarter for the first couple of years. How exactly it will ramp up remains to be seen. But typically, for all the projects that we have done, we consider 2 to 3 years as an establishment period. The specialty mix will be identical to all other hospitals. We will offer all services here beginning from child birth to transplantation, as I have said. The revenues should be in line with the Mumbai region, Thane hospital that we have. The ARPOB, of course, is also representative of the case mix. So initially, when a hospital has started, it has relatively lesser load of complex services or tertiary quaternary work and more load of primary secondary work. So as the hospital gains maturity, the ARPOB should converge. But in the earlier periods, ARPOBs will look smaller than the Thane hospital.

Okay. And what will be the time line for breakeven of this hospital and EBITDA drag for the first 2 to 3 years?

By end of year 2, we expect to be EBITDA breakeven.

And third question is, could you tell us the ARPOB of Q3 '26 on a consol basis?

ARPOB of Q3 '26 on consol basis is, 68,000.

68,000. And occupancy?

Occupancy is 61.4%.

The next question comes from the line of Kritika Damani with Prospera Financial Solutions.

Congratulations on a strong quarter. I know despite the sustained EBITDA margins, depreciation and finance costs have been rising due to recent and ongoing CapEx, how do we -- how should we think about the margin trajectory over the next few quarters as the new assets start contributing, but the costs are already in the P&L?

So Kritika, on the 3 operating hospitals, 2 are near maturity. So they should have similar margins. Indore is in its growth phase. We should expect slightly incremental margins from Indore over the next couple of years. And Dombivli, as I just said a short while back, should lose money for the first year or 2. So there will be a little bit of drag on the consol numbers on account of Dombivli for the next couple of years.

And my second question is with the multiple greenfield hospital under development alongside the mature hospital running, what internal metrics do you monitor most closely to ensure growth does not begin to dilute operational control or the clinical outcomes?

So both are completely independent teams. The project team has very little or nothing to do with the operations and the clinical operating teams, the medical teams have absolutely nothing to do with the new projects going on. So both of them have their separate roles cut out very clearly and new greenfields coming up have 0 impact on our clinical performance or operational performance.

Next question comes from the line of Himanshu Binani with Anand Rathi.

So sir, I have one question basically regarding to -- now the European trade deal is like largely done. So what we are seeing is that there has been like an absolute decrease in the import duties of medical equipment. So how one should actually look into the CapEx numbers going forward as in what is your initial understanding in terms of the CapEx, which can be reduced or there is like any sort of like saving into the CapEx numbers for you as well as for the industry?

I have 2 understandings. One is that headlines are different and fine prints and implementation is different. So I would wait to see how it gets implemented and what is in the fine print. And the other thing, just to set context also for everybody's benefit is that even though a lot of companies are headquartered today in Europe and the U.S., a lot of them have manufacturing facilities in China. So the country of export becomes China and the deal with Europe, I don't know how much impact it would have in machines being shipped out of China.

Okay. Got it. And sir, second question is on the Dombivli project. So what would be the initial like the EBITDA drag from that hospital for the first 2 years?

So remains to be seen. In the past, as I have said that our previous hospital experience is first year, something between INR 2 crores to INR 3 crores a month should be the average for the first year. But yes, let us see how this shapes.

[Operator Instructions] Next question comes from the line of [ Kaustav Bubna ] with [BMSPL Capital].

So I basically wanted to understand for all the hospitals you have -- are you -- what is your -- what's your strategy when you find land to create a new hospital? Are these hospitals in areas where you have no competition around you? And then if that's the case, how do you get good doctors and good faculty if these hospitals are not in -- how do I say it, in common areas, where is accessible -- easily accessible to good faculty and doctors?

Yes. So Kaustav, the metric for selection of locations is multifold. A, we are currently only looking at large cities in Western India. Typically in, when you are in a large city, it is also a proxy for HR and availability of manpower, including doctors. But within the large cities, we do look for those specific micro markets where the resident population is very high. And in the near vicinity, there would be a relatively low supply of high-end tertiary care services. This does not mean that there are no other hospitals because all large cities have covered, but it means that they are predominantly supplied by Tier 2 hospitals. The other thing which I must highlight is that the Tier 2 hospital is Tier 2 because of infrastructure and not necessarily because of manpower. A lot of these doctors in big cities, they are all trained similarly to, for example, doctors in Dombivli and doctors in South Bombay, would be classmates in the same medical school. For example, they may be from JJ or KEM or whatever. But just based on where they live and work, the quality of infrastructure and technology available to them may not be commensurate with their qualifications, and they make do with what they have. So when we enter these micro markets, it becomes a natural choice for a lot of these skilled medical practitioners to want to affiliate and associate with us. And it becomes a win-win symbiotic kind of association. So I hope that gives you some color and understanding on what we are doing and how.

So is this the same strategy for your Pune hospitals, too, the one that's coming up? Is it the same strategy across every single hospital that you're trying to...

So far, yes. Yes.

Okay. And I wanted to understand 3 years or 5 years down the line, what is our ARPOB target? I mean are we looking to with -- is there some level of offerings which have higher average revenue per bed which hospital currently does not undertake? I mean just could you strategically give some indication on will ARPOBs remain at similar levels? Or are we trying to increase higher ARPOB offerings?

So I'll answer the second question first. There is no service that we don't offer currently. We practice all branches of medicine and offer critical, tertiary, quaternary level services in all branches of medicine. We do not have any ARPOB target, either now nor for the future. We think that this ARPOB number is more of a byproduct of what you do. We are not looking at or chasing any specific ARPOB number. We will continue to provide all services in all the hospitals because that aligns with our operating and clinical philosophy. We don't want to have narrowly focused hospitals. We want to have broad spectrum full-service hospitals. And irrespective of which branch generates how much ARPOB, honestly, we don't track it internally also. So yes, whatever happens, happens. Generally, in the initial phases of operations, as I was saying earlier, the ARPOBs are lower because you do more of primary, secondary work. But as the hospital matures, the ARPOB also reaches maturity. After which, it only grows in line with inflation. So that would be my broad guidance to you that the mature asset ARPOBs should grow in line with inflation and the newer hospitals should grow a little faster in the earlier phases. And once they mature, they should grow in line with inflation. But no, there is no target.

[Operator Instructions] Next question comes from the line of Amit Thawani with Clear Blue Capital.

I think this is the first quarter we've reported single-digit top line growth. Can you explain what has happened this quarter?

Nothing has happened. Thank you for bringing it to my notice. I have not noticed that. But as I -- again, a couple of questions back said that health care cannot be monitored on quarter-to-quarter. Also, [Technical Difficulty] finite capacity, very soon, I would hope that all the mature hospitals are able to report 0 growth because they are already at maturity. So the growth eventually comes from new and upcoming hospitals where you start from 0. [Thane], Now does not really have too much ability to generate more occupancy growth. Pune, the opportunity is narrowing. Indore, still definitely has opportunity for higher growth, and we hope to see that play out over the next couple of years.

But anything -- any issue on the payer side? I mean we had some problem with insurer companies as an industry. I'm not sure what that problem -- how severe that problem was with Jupiter?

No, we have not had any serious problem with the payer companies. We have had largely uninterrupted services for almost all payers. We also have not had any unusual friction with the payer community. So yes, I would not attribute anything to friction with the payers.

Do you see -- any takeaways for us from the new EU-India trade deal on medical tourism?

I have not caught if there is any impact on medical tourism per se for the EU deal. I'm not sure if there is, but I will look it up. On the import duty side, as the question some time back, if it does play out the way it is publicized, especially those equipment being shipped out of Europe, hopefully should get cheaper, and that should, to some extent, at least help us counter the depreciating rupee. So that might be welcome.

Got it. My last question, sorry, I think I might have missed the answer for this, can you tell me what the Y-o-Y growth in ARPOB is? And yes, if you can just break up the revenue growth into ALOS, ARPOB?

ALOS, I don't have -- what I have is last year, ALOS was for 9 months, 3.88. This point in time, it is 3.85. So largely similar. ARPOB was 59,000 plus something, and this time, it is 66,000.

So almost entire 9% growth -- 10% growth this quarter is from ARPOB?

Yes.

Next question comes from the line of [Aryamaan] with Prudent IM.

Just one question from my side. Sir, what could be -- this is in respect to the CGHS price hike? So what could be -- could you benefit from this? And what's the time line you see benefit at all?

So your voice is muffled, but what I heard is you were asking about CGHS. Is that correct?

Yes, CGHS, the price hikes. Yes.

Yes. So we currently don't have any CGHS exposure on our P&L. So as we stand today, it does not impact us. But I understand that the CGHS rates are revised after the period of 10 years, and there is a substantial hike that the government has offered this time. But as far as Jupiter is concerned, you will not see any impact on that account.

Next question comes from the line of [Jay Jain] with [JJ Investments].

Sir, just one question from my side. Last year, we added 78 beds at Indore hospital. How is the hospitals overall performance since commissioning of those beds, particularly in terms of occupancy ramp-up and ARPOB growth, if you can just highlight us?

Yes, Jay, you are right. We added about 78 beds last year. We have on absolute -- of course, because of a larger base, the percentage occupancy is lower in Indore. But on an absolute term, I'm happy to confirm to you that the occupancy this year is higher than what it was last year and that the 78 beds have started getting utilized and are being put to use. The ARPOB side, we should have had a growth of, let me see, maybe 15-odd percent, I think, on account of both inflation and this maturity phase as I was saying, you will see a higher ARPOB growth in the first 6-odd years and till it reaches maturity. After which, it only grows in line with inflation. So Indore ARPOB for the next couple of years should grow a little faster than inflation logically, and that is what we are also seeing play out.

Next question comes from the line of Rishi Kapoor with [indiscernible].

My question is regarding the demand supply situation. So I just want to have the general view, you got a view regarding this. So how is the demand supply situation evolving across the Thane, Pune and Indore, given the rising occupancies and ongoing capacity additions?

So in the current 3 locations, it is pretty much status quo. The population keeps increasing. The insurance penetration keeps increasing in large Indian cities. So on account of both those factors, the demand is still very high. I don't think the supply situation is enough in either of the 3 markets at a high quality. And I think that high-quality supply will very easily get absorbed in Thane, Pune and Indore, even if more were to come from where we stand today.

All right. And regarding specifically about the ARPOB growth that you talked about the new hospital that is coming. On the consolidated basis, any view on the ARPOB growth outlook for the next 1 to 3 years?

Yes. I don't know how it will really play out because there will be some drag from Dombivli and some positive from the other 3 on account of inflation and higher growth of Indore. So on a blended level, how it will play out, I have not really done too much modeling around it. But it -- Dombivli will be diluting. Indore will be a little higher than inflation. Thane, Pune will be inflation-linked growth.

Next question comes from the line of Ashutosh Nemani with JM Financial Family Office.

First question is so much bed addition for the next 2 years. There have been some concerns highlighted by the peers regarding availability of star doctors and specifically, nurses, also. So how do you foresee that? Do you see doctor costs rising substantially when all this capacity comes up in the industry?

So nurses is a national challenge, and there is nothing new. It has been a challenge for a long time. Not specific to one hospital or one location. There is no magic answer to it. I think it will continue to remain a challenge. On the doctor side, my view is that if you are in large cities, then you don't have too much of a problem. As you start going into smaller and smaller Tier 3 and those kind of locations, then the availability of doctors is much lower. And interestingly, the doctor cost in smaller cities is much higher than doctor cost in larger cities. But in the locations that we operate, it is not hard to find good doctors.

Could you just like quantitatively tell us what is doctor cost as a percentage of revenue? And how has it evolved in the past 2 to 3 years?

So I don't have quantitative numbers. But typically, the doctor cost varies between 20% and 25% of the top line. So -- and we have generally been in that range.

Okay. And the second question is regarding Thane operation. We are adding multi-specialty hospital. Any impact on occupancy level and senior doctor attrition...

Sorry, sorry, what is the question about Thane?

One of the peers has also added a hospital in that region. So any impact on doctor attrition you are seeing the occupancy level more or less stable?

No impact on doctor attrition. We have had one full-time doctor move. But, so I would call it 0 attrition.

[Operator Instructions] Next question comes from the line of Kaustav Bubna with BMSPL Capital.

I just had a few more questions. So in previous interviews, it was mentioned that you may think about adding a seventh hospital. So do you have any updates on that in terms of how you were thinking of where that -- how do you -- where do you think is a good location for your seventh hospital? How are you thinking about that, if so? And I think I have a broader vision question also along with that. I mean, how do you see -- what is your strategy really in terms of CapEx-led growth over the next decade, taking into situation, obviously, taking into understanding your perception of demand supply over the next decade? So if you could answer those questions.

So I'm happy to get a question about a decade and not a quarter. I like a longer-term thinking than a quarterly thinking, especially for health care. As the demand supply stands today, even now as we speak, there is a huge mismatch at a national level. Even at prominent high Tier 1 metro city levels, I think we still have a lot more supply to create than what we need. We have to replace some of the old secondary care nursing homes with respectable health care operators because nowhere else in the world is health care provided in 15, 20, 30-bedder nursing homes as it is provided in Mumbai and other cities of India. So on the supply side, there is -- I'm absolutely convinced that there is more needed than what the whole industry collectively will be able to deliver. The players today will be collectively able to deliver over the next decade. So I think the growth story on Indian health care is probably longer than a decade. There is just too much to be done. And along with that, as the time goes on, more and more cities progress, they become larger and they become centers which will be able to absorb large-scale hospitals because of rising population, rising income levels and higher insurance penetration. So at an industry level, I think it is a multi-decade story. It is not a yearly or certainly not quarterly story. As far as Jupiter is concerned, you are right in your observation, we are keen to do the seventh hospital as well. We remain committed to Western India for now. We are in discussions with a few opportunities currently, but I don't have any announcement to make about where that location will be and when it will really mature because we are keen to do a greenfield and land being land with all its uncertainties in India, you can't really go out and make predictions before you deliver.

So as a company, you -- over the next decade, you plan to participate in the supply growth. You will not -- it's not like, I want to stay at 8 hospitals, 7 hospitals and then let the supply grow as much, we won't grow anymore. You plan to grow with the supply growth. Is that a correct understanding as...

There is nothing else I know how to do. So we'll have to keep doing this.

Okay. And just one last question on the doctor aspect. I know it's an ongoing struggle. It's just part of the industry. But also, please, if you could help my understanding better because this question comes out of a little bit of lack of understanding and knowledge about exactly how this works and how it is currently. But let's take Reliance Hospital, for example, in Lokhandwala in Mumbai. I know that, that hospital offers now tells doctors that listen, visit us exclusively. And obviously, that would -- and they apparently provide a very nice package to doctors, which this incentivizes doctors to even go and look for other opportunities to say that, we'll compensate you well enough to be with us only. So are other hospitals also doing that apart from Reliance? And how does -- do we do that? And if we don't -- have only Reliance is there and other hospitals are doing that, how does that affect retaining the doctor talent?

So I don't have specific case studies on different hospitals. But I'll tell you of my thought process. My thought process is that in the long term, it is not sustainable to compensate people significantly above or significantly below industry standards. You have to be in line with the industry because significantly above naturally is inefficient. Significantly below you risk continual attrition and in unstable teams. So you have to be fair in your compensation models. As far as we are concerned, we have a mix of some doctors who choose to exclusively practice with us, and we are also okay if -- who we consider as respectable professionals, some of them would want to come on a visiting basis as well. But what we do endeavor and we have achieved is that all branches of medicine will have someone exclusively working with the hospital so that if a patient shows up at our door at no point in time, we are in a position to not deliver on the care. So we will have exclusive practitioners in all branches, but we will not insist on only having exclusive practitioners.

Okay. Great. And if I could just squeeze in one more. How do you -- I mean you see hospitals in South Bombay and all these known hospitals, not just across Bombay. A big selling point to get customers is to have the best known doctors perform surgeries and do consulting in their hospitals. So I mean since our locations are not the status quo patients in terms of accessibility from where those doctors live, like obviously, Dombivli would be a little further away from, let's say, where a very popular doctor lives who is known to be their best in the field, how does the company get those doctors, compensate those doctors or what provide attractive opportunities to those type of doctors to come and consult and operate at, let's say, Thane, Dombivli hospital of Jupiter?

So, Kaustav, the definition of popular is known amongst the people. So the question is which people. The doctors who you are defining as popular in South Bombay are unknown names in Coimbatore. So medicine is a local and a hyperlocal service. You definitely need known and trustworthy doctors who are available in the region where you can seek care. There are extremely good doctors in MD Anderson and in Cleveland Clinic. But unfortunately, South Bombay cannot access them. Does not mean South Bombay does not go to some other people who they consider popular. So that is similar for all locations in the world that each micro market will have people who are more popular, more qualified. And based on those locations, people will choose where they want to seek care.

Next question comes from the line of Shashi Ranjan with [Anand Capital].

Just for my enlightenment, can you help me understand, do we cater to PMJAY or Ayushman Bharat cases or extremely weaker section patients who come to us? And in case we cater to them, are we getting paid by the government on time?

So as you must have seen from our report, we have just 1% of the revenue coming in from the government scheme. So in our view, that is our social contribution. We only have government schemes for 2 branches: Radiation treatment for cancer; and congenital heart diseases for children -- pediatric heart problems. So these are the only 2 problems where we have government schemes. So it is not a meaningful impact on our P&L. And in any case, in our mind, it is a social contribution. So yes, they don't really impact us too much.

[Operator Instructions] Next question comes from the line of Amit Thawani with Clear Blue Capital.

I was just -- I wanted to pick your brain on what is the -- what you believe is the long-term ARPOB growth?

So I've just answered that at length earlier. ARPOB will grow in line with inflation for mature hospitals and faster in the first few years. Once it reaches maturity, it will be in line with inflation.

And just -- so -- when we renew with our insurers, what is the insurance renewal that we are taking from them?

Inflation-linked.

Which is price -- is it quantified in our contracts?

It can't be quantified in advance, but at the time of each renewal, it is negotiated.

Okay. At the time of renewal, we are negotiated based on what the prevailing inflation is?

Correct.

Okay. And what is -- is that -- because I believe our costs could go higher than inflation linked. I mean cost of nurses and doctors could be higher than inflation. So how is -- and our ARPOB is also going to be linked to inflation. So how is that going to impact our margins?

This is going to be a long answer, Amit. I think we should catch up separately.

If you can give it in a couple of lines or -- I'll appreciate it. I mean I just want to know if there is a long-term impact on our margins.

I don't know. Let us see whatever happens to the industry will happen. How the macroeconomics will play out, how the wages will happen over the next several years, what will be the impact of trade and CapEx and consumables and GST over the next multiple years, how will taxation play out, too much of astrology is difficult to do. I'm sorry, but I really don't have too many answers about this.

Fair, sir. Appreciate it. But last, there is something called a common empanelment program. We don't plan to join that, right?

No. Currently, there is nothing under discussion with Jupiter on common empanelment.

Ladies and gentlemen, that was the last question for today. We have reached the end of question-and-answer session. I would now like to hand the conference over to the management for closing comments.

Thank you, everyone. I hope that I have answered the questions satisfactorily. If anyone has more questions, please feel free to reach out to SGA, and they'll put you in touch with us. Thank you.

Thank you. On behalf of Jupiter Life Line Hospital Limited, that concludes this conference. Thank you for joining us. You may now disconnect your lines.